Form 4: Fractyl Health Executive Jay David Caplan Reports Share Transactions

Jay David Caplan, President and Chief Product Officer of Fractyl Health, Inc., reported the acquisition and sale of company shares following the vesting of restricted stock units.

Summary

• Jay David Caplan, President and Chief Product Officer at Fractyl Health, Inc., filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On November 10, 2024, 187,257 restricted stock units vested, each representing one share of common stock.
• Following the vesting, 64,197 shares were sold on November 11, 2024, at a price of $2.4696 per share for tax withholding purposes.
• After these transactions, Mr. Caplan directly owns 153,544 shares and indirectly owns 358,806 shares through a trust and 118,810 shares through a family trust.

Sentiment

Score: 5

Explanation: The document is a routine filing of stock transactions, with no indication of positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for executives receiving stock-based compensation, where shares are often sold to cover tax liabilities upon vesting.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they represent a small portion of the total outstanding shares.
• The sale of shares by an executive could be perceived as slightly negative, but it is a common practice for tax purposes.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Executive Holdings, Fractyl Health, GUTS